

Clive S Zent

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/526017/publications.pdf>

Version: 2024-02-01

127
papers

3,255
citations

172457

29
h-index

155660

55
g-index

127
all docs

127
docs citations

127
times ranked

3807
citing authors

#	ARTICLE	IF	CITATIONS
1	The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact. <i>Haematologica</i> , 2022, 107, 1460-1465.	3.5	2
2	Impact of sex on outcomes in patients with hairy cell leukemia (HCL): An HCL Patient Data Registry (PDR) analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7577-7577.	1.6	1
3	Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma. <i>Leukemia</i> , 2021, 35, 1788-1791.	7.2	29
4	Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 598-605.	1.3	1
5	Targeted therapy for treatment of patients with classical hairy cell leukemia. <i>Leukemia Research</i> , 2021, 102, 106522.	0.8	5
6	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. <i>Leukemia</i> , 2021, 35, 1864-1872.	7.2	28
7	Ibrutinib Restores Tumor-specific Adaptive Immunity in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 4465-4467.	7.0	1
8	Changing of the guard: <i>Leukemia Research</i> 2021. <i>Leukemia Research</i> , 2021, 100, 106510.	0.8	0
9	Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2021, 138, 2640-2640.	1.4	0
10	Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy. <i>American Journal of Hematology</i> , 2020, 95, E16-E18.	4.1	2
11	Multiple B cell malignancies in patients with chronic lymphocytic leukemia: epidemiology, pathology, and clinical implications. <i>Leukemia and Lymphoma</i> , 2020, 61, 1037-1051.	1.3	4
12	Complement Activation in the Treatment of B-Cell Malignancies. <i>Antibodies</i> , 2020, 9, 68.	2.5	4
13	Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance. <i>Blood</i> , 2020, 136, 2065-2079.	1.4	18
14	Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). <i>Leukemia and Lymphoma</i> , 2020, 61, 1636-1644.	1.3	1
15	Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment. <i>Leukemia and Lymphoma</i> , 2020, 61, 1627-1635.	1.3	11
16	High-resolution quantification of discrete phagocytic events by live cell time-lapse high-content microscopy imaging. <i>Journal of Cell Science</i> , 2020, 133, .	2.0	9
17	Initial treatment of B-cell polymphocytic leukemia with ibrutinib. <i>American Journal of Hematology</i> , 2020, 95, E108-E110.	4.1	8
18	A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 41-42.	1.4	6

#	ARTICLE	IF	CITATIONS
19	Ibrutinib Off-Target Inhibition Inhibits Antibody-Dependent Cellular Phagocytosis but Not Efferocytosis of CLL Cells. <i>Blood</i> , 2020, 136, 45-45.	1.4	4
20	Arrhythmia Burden in Patients with Indolent Lymphoma. <i>Blood</i> , 2020, 136, 6-7.	1.4	1
21	CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering. <i>Haematologica</i> , 2019, 104, 1841-1852.	3.5	38
22	Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice. <i>Blood</i> , 2019, 134, 682-682.	1.4	1
23	Cognitive function in chronic lymphocytic leukemia (CLL): Examining effects of disease, treatment, and inflammation.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11584-11584.	1.6	2
24	Diagnosis and management of complications of chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Acta Haematologica Polonica</i> , 2019, 50, 91-97.	0.3	1
25	Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. <i>Haematologica</i> , 2018, 103, 874-879.	3.5	329
26	Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies. <i>Leukemia and Lymphoma</i> , 2018, 59, 625-632.	1.3	57
27	Monoclonal antibody therapy in chronic lymphocytic leukemia. <i>Oncology Signaling</i> , 2018, 1, 11-13.	0.2	0
28	miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. <i>Blood</i> , 2018, 132, 2389-2400.	1.4	45
29	Management of melanoma in patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2018, 71, 43-46.	0.8	17
30	Outcomes of frontâ€line ibrutinib treated CLL patients excluded from landmark clinical trial. <i>American Journal of Hematology</i> , 2018, 93, 1394-1401.	4.1	52
31	Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies. <i>Cancer Immunology Research</i> , 2018, 6, 1150-1160.	3.4	57
32	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <i>Haematologica</i> , 2018, 103, 1511-1517.	3.5	135
33	Correlates of anxiety and depression in chronic lymphocytic leukemia (CLL) survivors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 153-153.	1.6	3
34	Racial, age, and sex disparities in chronic lymphocytic leukemia (CLL) patients treated with novel therapies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6577-6577.	1.6	0
35	Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9. <i>Clinical Immunology</i> , 2017, 181, 24-28.	3.2	11
36	Ibrutinib therapy for lymphoplasmacytic lymphoma. <i>American Journal of Hematology</i> , 2017, 92, E542-E544.	4.1	2

#	ARTICLE	IF	CITATIONS
37	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	1.4	193
38	Maxed out macs: physiologic cell clearance as a function of macrophage phagocytic capacity. <i>FEBS Journal</i> , 2017, 284, 1021-1039.	4.7	61
39	A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). <i>American Journal of Hematology</i> , 2016, 91, 308-312.	4.1	13
40	Chronic lymphocytic leukemia and proteomics: protein profiles and links with disease progression still need validation. <i>Leukemia and Lymphoma</i> , 2016, 57, 985-986.	1.3	0
41	Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions. <i>Journal of Immunology</i> , 2016, 197, 1762-1775.	0.8	50
42	What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research. <i>British Journal of Haematology</i> , 2016, 174, 835-846.	2.5	55
43	CLL: an acquired immunodeficiency disease. <i>Blood</i> , 2016, 128, 1908-1909.	1.4	3
44	Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study. <i>Leukemia and Lymphoma</i> , 2016, 57, 1585-1591.	1.3	11
45	Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells. <i>Molecular Immunology</i> , 2016, 70, 13-23.	2.2	26
46	Management of Chronic Lymphocytic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 164-175.	3.8	24
47	Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates. <i>Leukemia and Lymphoma</i> , 2015, 56, 2373-2378.	1.3	20
48	Infectious lymphadenitis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare, but important, complication. <i>Leukemia and Lymphoma</i> , 2015, 56, 311-314.	1.3	15
49	Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 119-124.	2.5	18
50	Infection in chronic lymphocytic leukemia: parsimony has its limits. <i>Leukemia and Lymphoma</i> , 2014, 55, 2683-2684.	1.3	0
51	Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2079-2084.	1.3	42
52	Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. <i>American Journal of Hematology</i> , 2014, 89, 757-765.	4.1	32
53	Induced Resistance to Ofatumumab-Mediated Cell Clearance Mechanisms, Including Complement-Dependent Cytotoxicity, in Chronic Lymphocytic Leukemia. <i>Journal of Immunology</i> , 2014, 192, 1620-1629.	0.8	48
54	Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis. <i>British Journal of Haematology</i> , 2013, 163, 326-333.	2.5	35

#	ARTICLE	IF	CITATIONS
55	Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. <i>Leukemia and Lymphoma</i> , 2013, 54, 476-482.	1.3	10
56	Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. <i>British Journal of Haematology</i> , 2013, 162, 774-782.	2.5	187
57	Hodgkin Transformation Of Chronic Lymphocytic Leukemia (CLL): Mayo Clinic Experience. <i>Blood</i> , 2013, 122, 1642-1642.	1.4	5
58	An Effective and Tolerable Chemoimmunotherapy Regimen For Relapsed/Refractory and Very-High Risk Chronic Lymphocytic Leukemia Combining Alemtuzumab With Pentostatin and Low Dose Rituximab. <i>Blood</i> , 2013, 122, 1641-1641.	1.4	0
59	The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087) <i>TJ ETQq1 1 0.784314 rgBT /Overl</i>	1.4	0
60	Monoclonal antibody (mAb)-based cancer therapy. <i>Oncolmmunology</i> , 2012, 1, 959-961.	4.6	21
61	Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 211-217.	1.3	82
62	Improving quality of life in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1247-1248.	1.3	3
63	Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. <i>Leukemia and Lymphoma</i> , 2012, 53, 2218-2227.	1.3	42
64	Very High Risk CLL Characterized by a "Double Hit" Clone with Both 11q22 and 17p13 Deletion.. <i>Blood</i> , 2012, 120, 2486-2486.	1.4	0
65	Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab, Rituximab, and PGG Beta Glucan: A Phase I Clinical Trial. <i>Blood</i> , 2012, 120, 1792-1792.	1.4	0
66	Clinical Utility of PET/CT Scanning in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 3903-3903.	1.4	0
67	Transformation of Chronic Lymphocytic Leukemia Into Diffuse Large B-Cell Lymphoma (Richter's) <i>TJ ETQq1 1 0.784314 rgBT /Overl</i>	1.4	0
68	Analysis of Stem Cell Transplant Referral in a Cohort of Newly Diagnosed Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , 2012, 120, 4252-4252.	1.4	0
69	FISHing for answers in proliferation centers of chronic lymphocytic leukemia lymph nodes. <i>Leukemia and Lymphoma</i> , 2011, 52, 946-947.	1.3	1
70	Multi-parameter prognostication in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011, 52, 1823-1824.	1.3	0
71	Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. <i>Leukemia and Lymphoma</i> , 2011, 52, 1425-1434.	1.3	12
72	Pentostatin, Alemtuzumab, and Low Dose Rituximab Is Effective Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL). <i>Blood</i> , 2011, 118, 1790-1790.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Resistance to Complement Dependent Cytotoxicity in CLL Cells From Patients Treated with Ofatumumab. <i>Blood</i> , 2011, 118, 2836-2836.	1.4	1
74	Lenalidomide Consolidation Appears to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL. <i>Blood</i> , 2011, 118, 3899-3899.	1.4	2
75	Axl Receptor Tyrosine Kinase Signaling Pathway and the p53 Tumor Suppressor Protein Exist In A Novel Regulatory Loop In B-Cell Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2011, 118, 799-799.	1.4	1
76	Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Prospective Case-Control Study of Newly Diagnosed Patients. <i>Blood</i> , 2011, 118, 3903-3903.	1.4	0
77	Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL. <i>Blood</i> , 2011, 118, 3898-3898.	1.4	1
78	Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2011, 118, 4152-4152.	1.4	1
79	In Patients Newly Diagnosed with Chronic Lymphocytic Leukemia the Absolute Monocyte Count At Presentation Is Directly Associated with Disease Progression Independently From Rai Staging or Cytogenetics. <i>Blood</i> , 2011, 118, 2835-2835.	1.4	0
80	The Prevalence of Serious Infectious Complications in a Cohort of Non-Referred Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Compared to Controls: Results of a Cohort Study. <i>Blood</i> , 2011, 118, 4610-4610.	1.4	0
81	FISH Scoring for CLL: Comparison of Methods That Assess Round Versus Non-Round Nuclei. <i>Blood</i> , 2011, 118, 3538-3538.	1.4	16
82	The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. <i>Cancer</i> , 2010, 116, 2201-2207.	4.1	89
83	CD5 ⁺ chronic B-cell lymphoproliferative disorders: Diagnosis and prognosis of a heterogeneous disease entity. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, S35-41.	1.5	29
84	CD5 ⁺ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma. <i>Leukemia Research</i> , 2010, 34, 1235-1238.	0.8	30
85	Autoimmune Complications in Chronic Lymphocytic Leukaemia (CLL). <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 47-59.	1.7	84
86	Detection of recurrent chromosomal defects in chronic lymphocytic leukemia/small lymphocytic lymphoma: Innovations and applications. <i>Leukemia and Lymphoma</i> , 2010, 51, 186-187.	1.3	0
87	Cell-mediated immunity in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 1775-1776.	1.3	3
88	Vitamin D Insufficiency and Prognosis In Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2010, 116, 2408-2408.	1.4	0
89	Monoclonal and Polyclonal Serum Free Light Chains and Clinical Outcome In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 2409-2409.	1.4	0
90	Survival of Patients with Clinically Identified Monoclonal B-Cell Lymphocytosis (MBL) Relative to the Age and Sex Matched General Population. <i>Blood</i> , 2010, 116, 700-700.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Interactions with the Microenvironment Protect Lymphoma B-Cells From Rituximab Induced Apoptosis and Could Represent a Therapeutic Target. <i>Blood</i> , 2010, 116, 3115-3115.	1.4	0
92	CLL Cells From Subjects Treated with Rituximab and Alemtuzumab Can Lose Target Antigen and Develop Resistance to Mab-Mediated Complement Dependent Cytotoxicity. <i>Blood</i> , 2010, 116, 3585-3585.	1.4	0
93	ATM Gene Point Mutation and Frameshift Mutation Are Found In High-Risk, Untreated Chronic Lymphocytic Leukemia Patients with Interstitial Deletion of Chromosome 11q and Uniparental Disomy of Chromosome 11q. <i>Blood</i> , 2010, 116, 2420-2420.	1.4	1
94	Immune Phenotyping and Naive T Cells as a Predictor of Response to Therapy In Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2010, 116, 1362-1362.	1.4	0
95	Infectious Complications In a Prospective Cohort of Community Based Newly Diagnosed Patients with Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2010, 116, 4610-4610.	1.4	0
96	Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. <i>Leukemia and Lymphoma</i> , 2009, 50, 1261-1268.	1.3	69
97	Management of autoimmune cytopenia complicating chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 863-864.	1.3	13
98	Whole Genome Copy Number Variation Analysis of Chronic Lymphocytic Leukemia (CLL) Cells From Early-Intermediate Stage, High Risk CLL Patients Prior to First Treatment Reveals New Loss of Heterozygosity and Duplication Events in the CLL Genome.. <i>Blood</i> , 2009, 114, 1265-1265.	1.4	0
99	Complex Interstitial Deletions of 11q and Copy-Neutral Loss of Heterozygosity of 11q Are Detected by Whole Genome Copy Number Variation Analysis of Early-Intermediate Stage, High Risk Chronic Lymphocytic Leukemia Patients.. <i>Blood</i> , 2009, 114, 1245-1245.	1.4	0
100	Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. <i>Cancer</i> , 2008, 113, 2110-2118.	4.1	67
101	Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. <i>Leukemia Research</i> , 2008, 32, 1849-1856.	0.8	85
102	CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. <i>British Journal of Haematology</i> , 2008, 140, 537-546.	2.5	152
103	The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. <i>British Journal of Haematology</i> , 2008, 141, 615-621.	2.5	101
104	The role of alemtuzumab in the treatment of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 175-176.	1.3	1
105	Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients. <i>Journal of Clinical Investigation</i> , 2008, 118, 306-315.	8.2	20
106	CD5+ Chronic B-Cell Lymphoproliferative Disorders Could Contain a Novel Disease Entity.. <i>Blood</i> , 2008, 112, 2065-2065.	1.4	1
107	Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based Chemoimmunotherapy. <i>Blood</i> , 2008, 112, 43-43.	1.4	5
108	Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. <i>Blood</i> , 2007, 109, 405-411.	1.4	278

#	ARTICLE	IF	CITATIONS
109	Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2007, 139, 398-404.	2.5	76
110	A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2007, 110, 121-121.	1.4	31
111	Crosstalk between Chronic Lymphocytic Leukemia (CLL) B-Cells and Marrow Stromal Cells: Implication for CLL B-Cell Activation and Survival.. <i>Blood</i> , 2007, 110, 337-337.	1.4	1
112	A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2007, 110, 124-124.	1.4	2
113	Smudge Cells on Routine Blood Smear Predict Clinical Outcome in Chronic Lymphocytic Leukemia: A Universally Available Prognostic Test.. <i>Blood</i> , 2006, 108, 2785-2785.	1.4	1
114	Initial Presentation and Prognostic Factors in 286 Patients with T-Cell Large Granular Lymphocyte Leukemia.. <i>Blood</i> , 2006, 108, 300-300.	1.4	5
115	The Pentostatin, Cyclophosphamide, and Rituximab Regimen (PCR) Is Highly Active and Well Tolerated Regardless of Patient Age, Creatinine Clearance, and Performance Status: Analysis of a Multi-Center Phase II Trial.. <i>Blood</i> , 2006, 108, 36-36.	1.4	3
116	Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274).. <i>Blood</i> , 2006, 108, 530-530.	1.4	6
117	Proteomic Analysis of Chronic Lymphocytic Leukemia Cells Identifies Vimentin as a Novel Prognostic Factor for Aggressive Disease.. <i>Blood</i> , 2005, 106, 707-707.	1.4	14
118	Loss of p53 Is Due to Rearrangements in a ~6,400 kb Region of Low Copy Repeats near the Centromere of Chromosome 17 in Chronic Lymphocytic Leukemia (B-CLL).. <i>Blood</i> , 2005, 106, 3255-3255.	1.4	0
119	Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005, 106, 5420-5420.	1.4	0
120	Submicroscopic Interstitial Deletions in 13q14 Are Detectable in Metaphase Cells by Fluorescence In Situ Hybridization (FISH) with D13S319 in Chronic Lymphocytic Leukemia (B-CLL).. <i>Blood</i> , 2005, 106, 3278-3278.	1.4	0
121	Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia. <i>Current Oncology Reports</i> , 2004, 6, 348-354.	4.0	9
122	Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. <i>Leukemia Research</i> , 2004, 28, 495-507.	0.8	58
123	Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) have a Markedly Increased Rate of Second Malignancy, which is the Most Common Cause of Death. <i>Leukemia and Lymphoma</i> , 2004, 45, 507-513.	1.3	66
124	Interphase Fluorescence In Situ Hybridization (FISH) with an IgH Probe Is Important in the Management of Patients with a Clinical Diagnosis of Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2004, 104, 1919-1919.	1.4	1
125	Update on monoclonal antibody therapy in chronic lymphocytic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2004, 2, 107-13.	0.3	2
126	Localized herpes simplex lymphadenitis mimicking large-cell (Richter's) transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2001, 68, 287-291.	4.1	16

#	ARTICLE	IF	CITATIONS
127	Vancomycin-induced thrombocytopenia. , 1999, 62, 122-123.		19